|
|
|
|
|
|
Companies > Clinical
|
|
|
Cleveland BioLabs (NASDAQ: CBLI) is developing new drugs to protect human tissues from injury caused by acute stresses such as radiation, chemotherapy and ischemias. The company is also leveraging its expertise in apoptosis to develop novel cancer therapeutics.
Funders:
Sunrise Equity Partners
|
|
|
|
|